Xencor | XNCR - Current Assets


Xencor reported $599.82M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cytokinetics USD 916.97M 60.37M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Xencor USD 599.82M 81.38M Dec/2025